Palo Alto Investors LP Makes New $3.19 Million Investment in Oruka Therapeutics, Inc. $ORKA

Palo Alto Investors LP bought a new position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 33,546 shares of the company’s stock, valued at approximately $3,192,573. Oruka Therapeutics comprises 0.0% of Palo Alto Investors LP’s holdings, making the stock its 29th biggest holding. Palo Alto Investors LP owned approximately 0.05% of Oruka Therapeutics as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new stake in shares of Oruka Therapeutics during the 1st quarter worth $2,505,000. JPMorgan Chase & Co. lifted its holdings in shares of Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares in the last quarter. Legal & General Group Plc acquired a new stake in Oruka Therapeutics during the second quarter worth approximately $28,000. Rhumbline Advisers acquired a new stake in shares of Oruka Therapeutics during the second quarter valued at about $320,000. Finally, New York State Common Retirement Fund bought a new position in shares of Oruka Therapeutics in the second quarter valued at $96,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Leerink Partners set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, April 30th. HC Wainwright reissued a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Wedbush reissued an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Guggenheim restated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $134.30.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $111.84, for a total transaction of $782,880.00. Following the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $3,659,181.12. The trade was a 17.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 12,583 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the transaction, the director directly owned 38,743 shares of the company’s stock, valued at $2,716,271.73. The trade was a 24.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,116 shares of company stock worth $6,636,533 over the last ninety days. Corporate insiders own 23.49% of the company’s stock.

Oruka Therapeutics Trading Down 5.6%

Oruka Therapeutics stock traded down $5.40 during mid-day trading on Friday, hitting $91.14. The company had a trading volume of 589,422 shares, compared to its average volume of 1,118,875. The company’s fifty day moving average is $94.23 and its 200-day moving average is $67.34. Oruka Therapeutics, Inc. has a 12-month low of $14.61 and a 12-month high of $115.51. The company has a market capitalization of $6.03 billion, a price-to-earnings ratio of -44.90 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, sell-side analysts expect that Oruka Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.